Acadia Pharmaceuticals, Inc. (ACAD) Reports In-Line Q4 Loss
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $29.50 +1.58%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) reported Q4 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $588 thousand versus the consensus estimate of $550 thousand.
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Is the global equity rally broadening? UBS weighs in
- BMO starts chip stocks coverage: Here are its preferred picks
- Vireo Growth completes acquisition of C21 Investments
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
